Research programme: non-absorbed polymeric therapeutics - Relypsa

Drug Profile

Research programme: non-absorbed polymeric therapeutics - Relypsa

Alternative Names: RLY 6002

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Relypsa
  • Class Polymers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus
  • Research Cardiovascular disorders; Kidney disorders; Metabolic disorders

Most Recent Events

  • 02 Sep 2016 Relypsa has been acquired by Vifor Pharma
  • 21 Jul 2016 Galenica enters into a definitive merger agreement to acquire Relypsa .
  • 14 Mar 2014 Early research in Metabolic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top